KBC Group
MRNA icon

KBC Group’s Moderna MRNA Stock Holding History

KBC Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$807K Sell
11,517
-237
-2% -$12.3K ﹤0.01% 759
2026
Q1 		$597K Sell
11,754
-1,088
-8% -$50.8K ﹤0.01% 770
2025
Q4 		$379K Sell
12,842
-10,536
-45% -$286K ﹤0.01% 755
2025
Q3 		$604K Hold
23,378
– – ﹤0.01% 696
2025
Q2 		$645K Sell
23,378
-21,083
-47% -$555K ﹤0.01% 685
2025
Q1 		$1.26M Buy
44,461
+1,058
+2% +$37.5K ﹤0.01% 645
2024
Q4 		$1.8M Sell
43,403
-38,943
-47% -$1.86M 0.01% 708
2024
Q3 		$5.5M Sell
82,346
-56,297
-41% -$5.17M 0.02% 457
2024
Q2 		$16.5M Sell
138,643
-380,888
-73% -$48.2M 0.05% 269
2024
Q1 		$55.4M Buy
519,531
+460,560
+781% +$46.4M 0.18% 124
2023
Q4 		$5.87M Sell
58,971
-6,890
-10% -$580K 0.02% 439
2023
Q3 		$6.8M Sell
65,861
-96,216
-59% -$10.7M 0.03% 411
2023
Q2 		$19.7M Sell
162,077
-24,182
-13% -$3.23M 0.08% 226
2023
Q1 		$28.6M Buy
186,259
+81,233
+77% +$13.4M 0.12% 167
2022
Q4 		$18.9M Buy
105,026
+19,079
+22% +$3.12M 0.09% 214
2022
Q3 		$10.2M Sell
85,947
-2,162
-2% -$328K 0.05% 290
2022
Q2 		$12.6M Buy
88,109
+66,507
+308% +$9.51M 0.06% 277
2022
Q1 		$3.72M Sell
21,602
-58,829
-73% -$9.9M 0.01% 471
2021
Q4 		$20.4M Sell
80,431
-76,839
-49% -$22.5M 0.07% 259
2021
Q3 		$60.5M Buy
157,270
+45,898
+41% +$16.9M 0.22% 111
2021
Q2 		$26.2M Buy
111,372
+15,829
+17% +$2.83M 0.09% 222
2021
Q1 		$12.5M Buy
95,543
+43,931
+85% +$6.37M 0.05% 333
2020
Q4 		$5.39M Sell
51,612
-51,330
-50% -$5.19M 0.02% 451
2020
Q3 		$7.28M Buy
102,942
+19,952
+24% +$1.39M 0.04% 342
2020
Q2 		$5.33M Buy
+82,990
New +$4.54M 0.04% 393

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

KBC Group's MRNA Position: Q2 2026 in Review

KBC Group reduced its Moderna (MRNA) stake by 2% in Q2 2026, selling an estimated $12.3K and leaving 11,517 shares worth $807K. The position accounts for ﹤0.01% of the portfolio, ranked #759.

KBC Group first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $60.5M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • KBC Group held 11,517 shares of Moderna worth $807K as of Q2 2026.
  • KBC Group sold 237 Moderna shares in Q2 2026, an estimated $12.3K.
  • Moderna made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #759 holding.
  • KBC Group first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • KBC Group's Moderna position peaked at $60.5M in Q3 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.